Wenxiang Ji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenxiang Ji has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Shun Lu
Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
4 shared publications Yongfeng Yu
Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
2 shared publications- Alice Sze Tsai Wong
School of Biological Sciences, University of Hong Kong, Hong Kong, China
1 shared publication Fan Li
State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
1 shared publication- Jiachen Chen
State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
1 shared publication - Jie Qian
Department of Emergency Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication
Latest Publications
- 4 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (763) , eadl3598
PTPRT loss enhances anti–PD-1 therapy efficacy by regulation of STING pathway in non–small cell lung cancer
With the revolutionary progress of immune checkpoint inhibitors (ICIs) in non–small cell lung cancer, identifying patients with cancer who would benefit from ICIs has become critical and urgent. Here, we report protein tyrosine phosphatase receptor type T (PTPRT) loss as a precise and convenient predictive marker independent of PD-L1 expression for anti–PD-1/PD-L1 axis therapy. Anti–PD-1/PD-L1 axis treatment markedly increased progression-free survival in patients with PTPRT-deficient tumors. PTPRT-deficient tumors displayed cumulative DNA damage, increased cytosolic DNA release, and higher tumor mutation burden. Moreover, the tyrosine residue 240 of STING was identified as a direct substrate of PTPRT. PTPRT loss elevated phosphorylation of STING at Y240 and thus inhibited its proteasome-mediated degradation. PTPRT-deficient tumors released more IFN-β, CCL5, and CXCL10 by activation of STING pathway and increased immune cell infiltration, especially of CD8 T cells and natural killer cells, ultimately enhancing the efficacy of anti–PD-1 therapy in multiple subcutaneous and orthotopic tumor mouse models. The response of PTPRT-deficient tumors to anti–PD-1 therapy depends on the tumor-intrinsic STING pathway. In summary, our findings reveal the mechanism of how PTPRT-deficient tumors become sensitive to anti–PD-1 therapy and highlight the biological function of PTPRT in innate immunity. Considering the prevalence of PTPRT mutations and negative expression, this study has great value for patient stratification and clinical decision-making.
- 4 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (763) , eadl3598
PTPRT loss enhances anti–PD-1 therapy efficacy by regulation of STING pathway in non–small cell lung cancer
With the revolutionary progress of immune checkpoint inhibitors (ICIs) in non–small cell lung cancer, identifying patients with cancer who would benefit from ICIs has become critical and urgent. Here, we report protein tyrosine phosphatase receptor type T (PTPRT) loss as a precise and convenient predictive marker independent of PD-L1 expression for anti–PD-1/PD-L1 axis therapy. Anti–PD-1/PD-L1 axis treatment markedly increased progression-free survival in patients with PTPRT-deficient tumors. PTPRT-deficient tumors displayed cumulative DNA damage, increased cytosolic DNA release, and higher tumor mutation burden. Moreover, the tyrosine residue 240 of STING was identified as a direct substrate of PTPRT. PTPRT loss elevated phosphorylation of STING at Y240 and thus inhibited its proteasome-mediated degradation. PTPRT-deficient tumors released more IFN-β, CCL5, and CXCL10 by activation of STING pathway and increased immune cell infiltration, especially of CD8 T cells and natural killer cells, ultimately enhancing the efficacy of anti–PD-1 therapy in multiple subcutaneous and orthotopic tumor mouse models. The response of PTPRT-deficient tumors to anti–PD-1 therapy depends on the tumor-intrinsic STING pathway. In summary, our findings reveal the mechanism of how PTPRT-deficient tumors become sensitive to anti–PD-1 therapy and highlight the biological function of PTPRT in innate immunity. Considering the prevalence of PTPRT mutations and negative expression, this study has great value for patient stratification and clinical decision-making.
- Open Access
- 3 November 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 955800
SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers
Background: The emergence of immune checkpoint inhibitors (ICIs) is one of the most promising breakthroughs for the treatment of multiple cancer types, but responses vary. Growing evidence points to a link between developmental signaling pathway-related genes and antitumor immunity, but the association between the genomic alterations in these genes and the response to ICIs still needs to be elucidated.Methods: Clinical data and sequencing data from published studies and our cohort were collected to analyze the association of the mutation status of SMO with the efficacy of ICI therapy in the non-small cell lung cancer (NSCLC) cohort and the pan-cancer cohort. Furthermore, the correlation between SMO mutation and immunotherapeutic biomarkers such as immune cell infiltration, immune-related genes, and underlying signaling pathways was analyzed. Three SMO mutant plasmids were transfected into cells to explore the SMO mutation status in the context of its expression and cell growth.Result: In the NSCLC discovery cohort, the median progression-free survival in the SMO mutant (SMO_MUT) was longer than that in the wild type (SMO_WT) (23.0 vs. 3.8 months, adjusted p = 0.041). This finding was further confirmed in the NSCLC validation cohort (8.7 vs. 5.1 months, adjusted p = 0.013). In the pan-cancer cohort (n = 1,347), a significant overall survival advantage was observed in patients with SMO mutations [not reached (NR) vs. 18 months, adjusted p = 0.024]. In the subgroup analysis, the survival advantage of SMO_MUT against SMO_WT was prominent and consistent across genders, ages, treatment types, cancer types, and the tumor mutation burden (TMB) status (all pinteraction > 0.05). In an in vitro experiment, we found that both the mutant and wild-type plasmids can promote the expression of SMO, but the mutant plasmid had lower SMO mRNA and protein levels than the wild type. In CCK-8 experiments, we found that SMO_MUT plasmids can improve the growth of Calu-1 and PC-9 cells, but this capability varied between different mutations and cells. Upon further exploration, the SMO mutation status was found to be related to a higher TMB, more neoantigen load, more DNA damage repair (DDR) mutations, higher microsatellite instability (MSI) score, and higher CD8+ T-cell infiltration.Conclusions: The SMO mutation status is an independent prognostic factor that can be used to predict better clinical outcomes of ICI treatment across multiple cancer types.
- 3 November 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 955800
Open AccessSMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers
Background: The emergence of immune checkpoint inhibitors (ICIs) is one of the most promising breakthroughs for the treatment of multiple cancer types, but responses vary. Growing evidence points to a link between developmental signaling pathway-related genes and antitumor immunity, but the association between the genomic alterations in these genes and the response to ICIs still needs to be elucidated.Methods: Clinical data and sequencing data from published studies and our cohort were collected to analyze the association of the mutation status of SMO with the efficacy of ICI therapy in the non-small cell lung cancer (NSCLC) cohort and the pan-cancer cohort. Furthermore, the correlation between SMO mutation and immunotherapeutic biomarkers such as immune cell infiltration, immune-related genes, and underlying signaling pathways was analyzed. Three SMO mutant plasmids were transfected into cells to explore the SMO mutation status in the context of its expression and cell growth.Result: In the NSCLC discovery cohort, the median progression-free survival in the SMO mutant (SMO_MUT) was longer than that in the wild type (SMO_WT) (23.0 vs. 3.8 months, adjusted p = 0.041). This finding was further confirmed in the NSCLC validation cohort (8.7 vs. 5.1 months, adjusted p = 0.013). In the pan-cancer cohort (n = 1,347), a significant overall survival advantage was observed in patients with SMO mutations [not reached (NR) vs. 18 months, adjusted p = 0.024]. In the subgroup analysis, the survival advantage of SMO_MUT against SMO_WT was prominent and consistent across genders, ages, treatment types, cancer types, and the tumor mutation burden (TMB) status (all pinteraction > 0.05). In an in vitro experiment, we found that both the mutant and wild-type plasmids can promote the expression of SMO, but the mutant plasmid had lower SMO mRNA and protein levels than the wild type. In CCK-8 experiments, we found that SMO_MUT plasmids can improve the growth of Calu-1 and PC-9 cells, but this capability varied between different mutations and cells. Upon further exploration, the SMO mutation status was found to be related to a higher TMB, more neoantigen load, more DNA damage repair (DDR) mutations, higher microsatellite instability (MSI) score, and higher CD8+ T-cell infiltration.Conclusions: The SMO mutation status is an independent prognostic factor that can be used to predict better clinical outcomes of ICI treatment across multiple cancer types.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5537
Abstract 5537: MGA mutation status affect tumor immunomicroenvironment and predict the effect of immune check point inhibitor: From NSCLC to pan-cancers analysis
Background: A critical and challenging process in immunotherapy is to identify cancer patients who could benefit from immune checkpoint inhibitors (ICIs). Exploration of predictive biomarkers could help to maximize the clinical benefits. Thus, this research aimed to explore the underlying association between MGA mutation and cancer immunotherapy in pan-cancers. Methods: Clinical data and sequencing data from published studies were collected and consolidated to analyze the association between MGA mutation status and efficacy of ICI therapy in NSCLC and pan-cancers cohort respectively. To better understand the role of MGA in cancer immunotherapy, the correlation between MGA and several immunotherapeutic biomarkers (TMB, NAL and MSI) was investigated. Furthermore, the correlation between MGA and tumor immune-microenvironment, such as immune cell infiltration, immune related genes, and underlying signaling pathways were analyzed. Results: MGA-MUT was enriched in patients responding to ICI therapy. In the pool NSCLC cohort (N = 262), significant differences were detected between MGA-MUT and MGA_WT patients regarding objective response rate (ORR, 52.2% vs 23.9%, p= 0.006), disease control rate (DCR,86.9% vs. 61.2%, p = 0.013), durable clinical benefit (DCB, 69.6% versus 36.7%, p= 0.003), and mPFS in MGA-MUT was 15.1 months much longer than 4.3 months in the MGA_WT (adjusted p=0.008). In the pool pan-cancers cohort (N = 1576), significant overall survival advantage was observed in MGA-MUT patients (HR = 0.67 [95%CI, 0.51 to 0.88], adjusted p= 0.007). In subgroup analysis, the survival advantage of MGA-MUT vs. MGA-WT was prominent and consistent across gender, drug type, cancer type. But the survival advantage was dramatically different between two age groups. In younger group(age≤60), the survival benefit receiving ICI treatment was prominent in MGA-MUT patients compared with Wildtype (mOS not reach [NR] vs 19 m, HR = 0.48 [95% CI 0.31-0.73], adjusted p = 0.002), but the discrepancy was not recurrent in the elders (age>60). In further exploring, we found that MGA mutation status was close connected higher tumor mutation burden, more neoantigen load, and higher MSI score. The CD8+ T cell and NK cell infiltration in MGA-MUT tumors were higher than its counterpart. Further GSEA analysis revealed enhanced anti-tumor immunity in MGA-MUT tumor, especially the cytosolic DNA sensing pathway recurrent in multiple cancer types. Conclusions: This research investigated the immunotherapeutic value of MGA in pan-cancers, indicating that MGA-MUT could serve as a potential predictive biomarker for immune checkpoint inhibitors, and providing preliminary evidence regarding the function of MGA mutation and its role in anti-tumor immunity. Citation Format: Wenxiang Ji, Shun Lu. MGA mutation status affect tumor immunomicroenvironment and predict the effect of immune check point inhibitor: From NSCLC to pan-cancers analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5537.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5537
Open AccessAbstract 5537: MGA mutation status affect tumor immunomicroenvironment and predict the effect of immune check point inhibitor: From NSCLC to pan-cancers analysis
Background: A critical and challenging process in immunotherapy is to identify cancer patients who could benefit from immune checkpoint inhibitors (ICIs). Exploration of predictive biomarkers could help to maximize the clinical benefits. Thus, this research aimed to explore the underlying association between MGA mutation and cancer immunotherapy in pan-cancers. Methods: Clinical data and sequencing data from published studies were collected and consolidated to analyze the association between MGA mutation status and efficacy of ICI therapy in NSCLC and pan-cancers cohort respectively. To better understand the role of MGA in cancer immunotherapy, the correlation between MGA and several immunotherapeutic biomarkers (TMB, NAL and MSI) was investigated. Furthermore, the correlation between MGA and tumor immune-microenvironment, such as immune cell infiltration, immune related genes, and underlying signaling pathways were analyzed. Results: MGA-MUT was enriched in patients responding to ICI therapy. In the pool NSCLC cohort (N = 262), significant differences were detected between MGA-MUT and MGA_WT patients regarding objective response rate (ORR, 52.2% vs 23.9%, p= 0.006), disease control rate (DCR,86.9% vs. 61.2%, p = 0.013), durable clinical benefit (DCB, 69.6% versus 36.7%, p= 0.003), and mPFS in MGA-MUT was 15.1 months much longer than 4.3 months in the MGA_WT (adjusted p=0.008). In the pool pan-cancers cohort (N = 1576), significant overall survival advantage was observed in MGA-MUT patients (HR = 0.67 [95%CI, 0.51 to 0.88], adjusted p= 0.007). In subgroup analysis, the survival advantage of MGA-MUT vs. MGA-WT was prominent and consistent across gender, drug type, cancer type. But the survival advantage was dramatically different between two age groups. In younger group(age≤60), the survival benefit receiving ICI treatment was prominent in MGA-MUT patients compared with Wildtype (mOS not reach [NR] vs 19 m, HR = 0.48 [95% CI 0.31-0.73], adjusted p = 0.002), but the discrepancy was not recurrent in the elders (age>60). In further exploring, we found that MGA mutation status was close connected higher tumor mutation burden, more neoantigen load, and higher MSI score. The CD8+ T cell and NK cell infiltration in MGA-MUT tumors were higher than its counterpart. Further GSEA analysis revealed enhanced anti-tumor immunity in MGA-MUT tumor, especially the cytosolic DNA sensing pathway recurrent in multiple cancer types. Conclusions: This research investigated the immunotherapeutic value of MGA in pan-cancers, indicating that MGA-MUT could serve as a potential predictive biomarker for immune checkpoint inhibitors, and providing preliminary evidence regarding the function of MGA mutation and its role in anti-tumor immunity. Citation Format: Wenxiang Ji, Shun Lu. MGA mutation status affect tumor immunomicroenvironment and predict the effect of immune check point inhibitor: From NSCLC to pan-cancers analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5537.
- Open Access
- 1 January 2022
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (2) , 41
Treatment preferences for epidermal growth factor receptor mutation-positive non-small cell lung cancer with brain metastasis: a large-scale survey from Chinese oncologists
Treatment preferences for epidermal growth factor receptor mutation-positive non-small cell lung cancer with brain metastasis: a large-scale survey from Chinese oncologists Yongfeng Yu, Jie Qian, Lan Shen, Wenxiang Ji, Shun Lu
- 1 January 2022
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (2) , 41
Open AccessTreatment preferences for epidermal growth factor receptor mutation-positive non-small cell lung cancer with brain metastasis: a large-scale survey from Chinese oncologists
Treatment preferences for epidermal growth factor receptor mutation-positive non-small cell lung cancer with brain metastasis: a large-scale survey from Chinese oncologists Yongfeng Yu, Jie Qian, Lan Shen, Wenxiang Ji, Shun Lu